Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
نویسندگان
چکیده
منابع مشابه
Autoimmune inflammatory myopathy after treatment with ipilimumab.
While human immunity is generally thought to protect against infectious agents, there is also evidence for immune surveillance against neoplastic diseases. Some malignant cells are able to evade or down-regulate this immune response through a variety of chemical mediators, rendering the host response ineffective and leading to poor prognoses. Immune mechanisms seem particularly important in the...
متن کاملNecrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies
Idiopathic inflammatory myopathies are an unusual group of myopathies with annual incidence of 1 in 100 000 people in the United States. Necrotizing autoimmune myopathy comprises only 16% of this group. It usually presents with severe proximal weakness, lower extremity weakness, and severe fatigue while very rarely does it present with dysphagia and respiratory muscle weakness. Statin use, canc...
متن کاملGastric Strongyloides Stercoralis in a Patient with Inflammatory Myopathy
Strongyloides stercoralis is a free living tropical and semitropical soil nematode which its larva penetrates skin. It can complete its life cycle in human body and causes autoinfection. Most patients have no frank symptoms. But respiratory, gastrointestinal and skin manifestation may occur. We report a 76 year old man admitted to emergency room with muscle weakness, dyspnea, nausea, v...
متن کاملTreatment of inflammatory myopathy with intravenous gamma globulin.
Intravenous immunoglobulin (IVIg) is a new modality used to help treat conditions associated with immune dysregulation. The inflammatory myopathies are a group of complex diseases including dermatomyositis, polymyositis, and inclusion-body myositis. Overall evaluation of IVIg in myopathy has been hampered by difficulty in accurately diagnosing and assessing disease activity. The lack of large, ...
متن کاملIpilimumab in patients with melanoma and autoimmune disease
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 2009
ISSN: 0317-1671,2057-0155
DOI: 10.1017/s0317167100007939